Valuation: Axsome Therapeutics, Inc.

Market Cap 10.16B 8.96B 8.47B 7.68B 14.41B 975B 14.54B 101B 39.09B 498B 38.13B 37.3B 1,598B P/E 2026 *
-69x
P/E 2027 * 41.9x
Enterprise Value 10.01B 8.83B 8.35B 7.57B 14.2B 961B 14.33B 99.98B 38.52B 491B 37.58B 36.76B 1,575B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 6.29x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-4.00%
1 week-9.42%
Current month-6.24%
1 month-6.47%
3 months-22.98%
6 months+19.05%
Current year+1.92%
1 week 182.1
Extreme 182.1
204.7
1 month 182.1
Extreme 182.1
229.62
Current year 152.28
Extreme 152.28
260.19
1 year 117.3
Extreme 117.3
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Exercice

Chief Operating Officer

30,000 0.0573%
8/6/26 Exercice

Chief Executive Officer

13,980 0.0272%
7/1/26 Exercice

Chief Executive Officer

148,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%-9.42%+59.42%+154.78% 10.16B
+3.13%+17.65%+730.79%+102.91% 78.76B
-0.23%-5.97%+33.09%-10.07% 75.12B
+0.21%+2.24%-6.14%-27.67% 61.14B
-2.68%-2.50%+5.03%+165.47% 46.07B
-1.07%-1.21%-9.92%+32.27% 47.57B
-0.71%+3.65%+65.30%-11.93% 33.79B
-1.30%-1.16%+48.97%+110.20% 25.3B
-0.26%-6.35%+2.84%+140.35% 21.34B
-0.64%-1.58%+60.16%+95.78% 15.36B
Average -0.76%-0.95%+98.95%+75.21% 41.46B
Weighted average by Cap. -0.11%+0.35%+155.48%+56.05%

Financials

2026 *2027 *
Net sales 964M 850M 804M 728M 1.37B 92.47B 1.38B 9.63B 3.71B 47.22B 3.62B 3.54B 152B 1.55B 1.36B 1.29B 1.17B 2.2B 149B 2.22B 15.46B 5.96B 75.85B 5.81B 5.68B 244B
Net income -142M -125M -118M -107M -201M -13.6B -203M -1.42B -545M -6.94B -532M -520M -22.3B 245M 216M 204M 185M 347M 23.48B 350M 2.44B 942M 11.99B 918M 898M 38.49B
Net Debt -148M -130M -123M -112M -209M -14.17B -211M -1.47B -568M -7.23B -554M -542M -23.23B -421M -371M -351M -318M -597M -40.4B -603M -4.21B -1.62B -20.63B -1.58B -1.55B -66.25B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
26-09-29 $186.14 -4.00% 1,577,447
26-09-28 $193.89 -0.62% 707,408
26-09-25 $195.09 -0.48% 838,181
26-09-24 $196.03 +1.33% 386,176
26-09-23 $193.45 -4.75% 912,995
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
186.14USD
Average target price
284.63USD
Spread / Average Target
+52.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock